BiotechTube

Iressa (Gefitinib)

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain Neoplasms

Conditions

Brain Neoplasms, Non Small Cell Lung Cancer

Trial Timeline

Jul 1, 2004 → Feb 1, 2006

NCT ID
NCT00234442

About Iressa (Gefitinib)

Iressa (Gefitinib) is a phase 2 stage product being developed by AstraZeneca for Brain Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT00234442. Target conditions include Brain Neoplasms, Non Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT00169221Phase 2Terminated
NCT00234442Phase 2Terminated
NCT00234468Phase 3Terminated
NCT00233636Phase 2Withdrawn

Competing Products

20 competing products in Brain Neoplasms

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Duloxetine + Sugar pillEli LillyPhase 2
52
Neurosteroid enantiomerOragenicsPhase 2
44
Patritumab deruxtecanDaiichi SankyoPhase 2
52
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
Eribulin MesylateEisaiPhase 1
33
Pembrolizumab + LenvatinibEisaiPhase 2
52
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
52
GLIADELEisaiPhase 2
52
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
33
abemaciclib + abemaciclibEli LillyPhase 2
52
JNJ-17299425Johnson & JohnsonPhase 2
52
ABT-888AbbViePhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
Trastuzumab deruxtecanAstraZenecaPhase 2
52
ExenatideAstraZenecaApproved
85
AZD5213AstraZenecaPhase 1
33
VorinostatMerckPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85